PIR and breast carcinoma: To sum up, the study provides structural basis for each mutation-induced conformational change and disclosed a possible way for the mutations’ role in the progression of Breast Cancer (BC); thus, PIR acts a potential therapeutic target or a biomarker in the future ahead.